Halozyme Shares Surge on Stellar Earnings and Strategic Acquisition

Halozyme Therapeutics witnessed a dramatic surge in its share price following the release of unexpectedly robust quarterly earnings and a substantial upward revision to its full-year guidance. The biotechnology firm not only delivered a powerful earnings beat but also signaled its commitment to future expansion through the strategic acquisition of Elektrofi.

For the third quarter of 2025, Halozyme reported adjusted earnings per share of $1.72, significantly outpacing the analyst consensus estimate of $1.61. The company’s revenue demonstrated remarkable strength, climbing 22% to reach $354 million and surpassing the projected $340.12 million.

A key driver behind this performance was a 52% explosion in license revenues, which hit $236 million. This surge was fueled by heightened demand for ENHANZE-based therapies, including DARZALEX SC, Phesgo, and VYVGART Hytrulo. Furthermore, the company's adjusted EBITDA saw a substantial 35% increase, landing at $248 million.

Bullish Outlook for 2025

Bolstered by these strong results, Halozyme’s management issued a significantly more optimistic forecast for the entirety of 2025. The updated projections include:

Should investors sell immediately? Or is it worth buying Halozyme Therapeutics?

• Total revenue in the range of $1.3 billion to $1.375 billion, representing growth of 28% to 35%.
• License revenues anticipated to be between $850 million and $880 million, equating to a 49% to 54% increase.
• Adjusted EBITDA forecasted at $885 million to $935 million, marking a 40% to 48% gain.
• Adjusted earnings per share expected to be between $6.10 and $6.50, indicating growth of 44% to 54%.

This pronounced upgrade to the company's financial outlook underscores the leadership's deep confidence in the continued commercial success of its ENHANZE technology platform.

Strategic Moves and Leadership Transition

Beyond the impressive financial metrics, Halozyme is actively shaping its future trajectory. The company has agreed to acquire Elektrofi for $750 million, with the potential for an additional $150 million in milestone payments. This acquisition is poised to broaden Halozyme's portfolio by adding the Hypercon technology and is expected to be finalized in the fourth quarter of 2025.

In a separate corporate development, the company announced that Chief Financial Officer Nicole LaBrosse will be stepping down by March 30, 2026. A search for her successor from outside the company is already underway.

Looking forward, management expressed confidence in its ability to secure a new ENHANZE partnership deal before the year's end. The integration of Elektrofi is projected to begin contributing additional license revenues as early as 2030, providing a clear pathway for sustained long-term growth.